Australia - English - Department of Health (Therapeutic Goods Administration)

body science international pty ltd - excipient ingredients: - as for each individual product contained within. this kit offers greentea tx100 in three different flavour options.

Australia - English - Department of Health (Therapeutic Goods Administration)

body science international pty ltd - aspartic acid, quantity: 200 mg; borax, quantity: 10.14 mg (equivalent: boron, qty 1.15 mg); heavy magnesium oxide, quantity: 356.11 mg (equivalent: magnesium, qty 214.77 mg); pyridoxine hydrochloride, quantity: 5.47 mg (equivalent: pyridoxine, qty 4.5 mg); zinc oxide, quantity: 15.56 mg (equivalent: zinc, qty 12.5 mg); menaquinone 7, quantity: 22.5 microgram; trigonella foenum-graecum, quantity: 72 mg (equivalent: trigonella foenum-graecum, qty 9 g); tribulus terrestris, quantity: 400 mg (equivalent: tribulus terrestris, qty 20 g); epimedium sagittatum, quantity: 3.33 mg (equivalent: epimedium sagittatum, qty 50 mg) - tablet, film coated - excipient ingredients: maltodextrin; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; croscarmellose sodium; crospovidone; povidone; purified water; macrogol 400; hypromellose; titanium dioxide; brilliant blue fcf; vanillin; carnauba wax; ethylcellulose; colloidal anhydrous silica; macrogol 8000 - enhance/promote/physical endurance/capacity/stamina ; aid/assist muscle growth ; helps enhance/promote healthy muscle mass ; helps enhance/improve/promote/increase muscle strength ; maintain/support muscle strength ; aphrodisiac/enhance/improve/promote healthy libido ; maintain/support healthy libido ; maintain/support healthy sexual function ; maintain/support testosterone level

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience australia pty ltd - clethodim; liquid hydrocarbon - emulsifiable concentrate - clethodim cyclohexanediones active 240.0 g/l; liquid hydrocarbon solvent other 606.0 g/l - herbicide - beetroot | cabbage | canola - see label | celery | chickpea - see label | cotton - refer to label | faba bean - see label | fiel - annual phalaris | annual ryegrass | barley grass | barnyard or water grass | blown grass | brome grass | crowsfoot grass | feathertop rhodes grass | johnson grass - seedling | liverseed or urochloa grass | paradoxa grass | red sprangletop grass | silver grass (v.bromoides) - suppression | summer grass | volunteer barley | volunteer oat | volunteer sorghum | volunteer wheat | wild oat | winter grass | annual blue grass | annual phalaris | annual poa | barnyard grass | bromus diandrus | bromus rigidus | canary grass | common oats | crab grass | goose grass | h. hexastichon | hairy rhodes grass | liverseed grass | native rhodes grass | triticum aestivum | woollytop rhodes grass

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: povidone; monobasic potassium phosphate; lactose monohydrate; gelatin; carbon black; sunset yellow fcf; shellac; indigo carmine; purified water; cellacefate; erythrosine; diethyl phthalate - mayne pharma erythromycin is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. infections due to listera monocytogenes. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is not suitable prior to genitourinary or gastrointestinal tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - capsule, modified release - excipient ingredients: purified talc; purified water; maize starch; gelatin; sucrose; methacrylic acid copolymer; ethylcellulose; hypromellose; macrogol 6000; diethyl phthalate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: gelatin; povidone; cellacefate; lactose monohydrate; monobasic potassium phosphate; diethyl phthalate; erythrosine; indigo carmine; carbon black; purified water; shellac; sunset yellow fcf - indications as at 22 may 2003: eryc is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is n ot suitable prior to genitourinary or gastrointestinal tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - capsule, modified release - excipient ingredients: sucrose; ethylcellulose; purified water; gelatin; macrogol 6000; maize starch; hypromellose; purified talc; diethyl phthalate; methacrylic acid copolymer; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 50 mg - capsule, modified release - excipient ingredients: hypromellose; methacrylic acid copolymer; gelatin; sucrose; purified talc; maize starch; purified water; ethylcellulose; diethyl phthalate; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; macrogol 6000; gelatin; purified water; diethyl phthalate; sucrose; ethylcellulose; maize starch; hypromellose; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain: kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness: kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - English - Department of Health (Therapeutic Goods Administration)

body science international pty ltd - ilex paraguariensis,paullinia cupana,turnera diffusa -